Grace Therapeutics, Inc. Total Liabilities and Equity
Grace Therapeutics, Inc. (GRCE) had Total Liabilities and Equity of $50.07 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-13
- 2026-06-30: Liabilities and Equity $50.07M.
- 2026-03-31: Liabilities and Equity $66.65M.
- 2025-12-31: Liabilities and Equity $68.49M.
- 2025-09-30: Liabilities and Equity $66.58M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $50.07M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $66.65M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $68.49M 10-Q · filed 2026-02-12 |
| 2025-09-30 | $66.58M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $69.81M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $71.99M 10-K · filed 2026-06-18 |
| 2024-12-31 | $61.22M 10-Q · filed 2025-02-13 |
| 2024-09-30 | $65.35M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $69.72M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $73.30M 10-K · filed 2025-06-23 |
| 2023-12-31 | $76.19M 10-Q · filed 2024-02-12 |
| 2023-09-30 | $78.21M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $73.03M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $79.12M 10-K · filed 2024-06-21 |
| 2022-12-31 | $116.80M 10-Q · filed 2023-02-14 |
| 2022-09-30 | $120.91M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $124.93M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $128.62M 10-K · filed 2023-06-23 |
| 2021-12-31 | $114.23M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $119.80M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $60.45M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $62.46M 10-K · filed 2022-06-21 |
| 2020-12-31 | $30.30M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $13.83M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $20.14M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $22.85M 10-K · filed 2021-06-22 |
| 2019-03-31 | $36.90M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |